DK3846788T3 - Pde11-hæmmere til anvendelse i behandling af parkinsons sygdom - Google Patents
Pde11-hæmmere til anvendelse i behandling af parkinsons sygdomInfo
- Publication number
- DK3846788T3 DK3846788T3 DK19783154.8T DK19783154T DK3846788T3 DK 3846788 T3 DK3846788 T3 DK 3846788T3 DK 19783154 T DK19783154 T DK 19783154T DK 3846788 T3 DK3846788 T3 DK 3846788T3
- Authority
- DK
- Denmark
- Prior art keywords
- parkinson
- disease
- treatment
- pde11 inhibitors
- pde11
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18192799 | 2018-09-05 | ||
| PCT/NL2019/050578 WO2020050722A1 (en) | 2018-09-05 | 2019-09-05 | Use of a pde11 or pde2 inhibitor for the treatment of parkinson's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3846788T3 true DK3846788T3 (da) | 2026-01-12 |
Family
ID=63517803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19783154.8T DK3846788T3 (da) | 2018-09-05 | 2019-09-05 | Pde11-hæmmere til anvendelse i behandling af parkinsons sygdom |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210330736A1 (da) |
| EP (1) | EP3846788B1 (da) |
| JP (2) | JP2021535180A (da) |
| CN (1) | CN112996492A (da) |
| DK (1) | DK3846788T3 (da) |
| ES (1) | ES3058213T3 (da) |
| FI (1) | FI3846788T3 (da) |
| PL (1) | PL3846788T3 (da) |
| WO (1) | WO2020050722A1 (da) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116173035A (zh) * | 2021-11-26 | 2023-05-30 | 中国科学院深圳先进技术研究院 | 双嘧达莫在抑制Mcl-1中的应用 |
| WO2025075499A1 (en) * | 2023-10-02 | 2025-04-10 | Universiteit Van Amsterdam | Reducing dopamine feed-back inhibition in dopaminergic cells by tadalafil. |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0967284A1 (en) * | 1998-05-28 | 1999-12-29 | Pfizer Limited | Phosphodiesterases |
| CA2407031A1 (en) * | 2000-04-19 | 2001-10-25 | Lilly Icos Llc | Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease |
| US20030032579A1 (en) * | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| FR2846653B1 (fr) * | 2002-10-30 | 2007-04-20 | Neuro3D | Inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations |
| US20070010450A1 (en) | 2003-06-13 | 2007-01-11 | Microbia, Inc., A Massachusetts Corporation | Methods and compositions for the treatment of gastrointestinal disorders |
| WO2005041957A1 (en) * | 2003-10-29 | 2005-05-12 | Pfizer Products Inc. | Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors |
| CN101495454A (zh) * | 2006-05-31 | 2009-07-29 | 查珀尔希尔北卡罗来纳大学 | 新型pde4抑制剂 |
| WO2008119057A2 (en) * | 2007-03-27 | 2008-10-02 | Omeros Corporation | The use of pde7 inhibitors for the treatment of movement disorders |
| US8637528B2 (en) * | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
| BRPI0911518A2 (pt) * | 2008-04-29 | 2017-06-13 | Pharnext | novas aproximações terapêuticas para o tratamento da doença de alzheimer e doenças relacionadas através de uma modulação de resposta ao estresse de célula |
| WO2011156453A2 (en) | 2010-06-09 | 2011-12-15 | Combimab, Inc. | Therapeutic peptides |
| US20150086481A1 (en) | 2011-07-28 | 2015-03-26 | Memorial Sloan-Kettering Cancer Center | Diagnosis and treatment of parkinson's disease |
| US9173884B2 (en) * | 2011-11-30 | 2015-11-03 | Trustees Of Boston College | Inhibitors of phosphodiesterase 11 (PDE11) |
| CA2871614C (en) * | 2012-04-27 | 2021-08-31 | Millennium Pharmaceuticals, Inc. | Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy |
| JP2013241354A (ja) * | 2012-05-18 | 2013-12-05 | Oriza Yuka Kk | ホスホジエステラーゼ2阻害剤 |
| EP3091983B1 (en) * | 2014-01-08 | 2019-10-02 | Intra-Cellular Therapies, Inc. | Pharmaceutical compositions comprising a pde-1 inhibitor and a pde-2 inhibitor |
| WO2016145614A1 (en) * | 2015-03-17 | 2016-09-22 | Merck Sharp & Dohme Corp. | Triazolyl pyrimidinone compounds as pde2 inhibitors |
| WO2017000276A1 (en) * | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic compounds as pde2 inhibitors |
-
2019
- 2019-09-05 US US17/271,978 patent/US20210330736A1/en active Pending
- 2019-09-05 CN CN201980066363.6A patent/CN112996492A/zh active Pending
- 2019-09-05 EP EP19783154.8A patent/EP3846788B1/en active Active
- 2019-09-05 WO PCT/NL2019/050578 patent/WO2020050722A1/en not_active Ceased
- 2019-09-05 PL PL19783154.8T patent/PL3846788T3/pl unknown
- 2019-09-05 FI FIEP19783154.8T patent/FI3846788T3/fi active
- 2019-09-05 ES ES19783154T patent/ES3058213T3/es active Active
- 2019-09-05 DK DK19783154.8T patent/DK3846788T3/da active
- 2019-09-05 JP JP2021512542A patent/JP2021535180A/ja active Pending
-
2024
- 2024-07-12 JP JP2024112678A patent/JP2024138492A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES3058213T3 (en) | 2026-03-09 |
| JP2021535180A (ja) | 2021-12-16 |
| WO2020050722A1 (en) | 2020-03-12 |
| FI3846788T3 (fi) | 2025-12-17 |
| EP3846788A1 (en) | 2021-07-14 |
| EP3846788B1 (en) | 2025-10-29 |
| JP2024138492A (ja) | 2024-10-08 |
| US20210330736A1 (en) | 2021-10-28 |
| PL3846788T3 (pl) | 2026-02-23 |
| CN112996492A (zh) | 2021-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3364997T3 (da) | Aspartoacylase genterapi til behandling af canavans sygdom | |
| MA45937A (fr) | Inhibiteurs d'amino pyrimidine ssao | |
| DK3681500T3 (da) | Anvendelse af pilocarpinhydrochlorid til behandling af presbyopi | |
| LT3472153T (lt) | Pirimidin-2-ilamino-1h-pirazolai kaip lrrk2 inhibitoriai, skirti naudoti neurodegeneracinių sutrikimų gydyme | |
| DK3806898T3 (da) | Gremlin-1-antagonist til anvendelse i behandling af cancer | |
| DK3405215T3 (da) | Fremgangsmåder til behandling af danon-sygdom og andre autofagilidelser | |
| ZA201805439B (en) | Bruton's tyrosine kinase inhibitors | |
| DK4014976T3 (da) | Aprocitentan til anvendelse i behandlingen af hypertension og relaterede sygdomme i kombination med valsartan | |
| DK3429571T3 (da) | Kombinationer af lsd1-hæmmere til anvendelse til behandling af neoplastiske sygdomme | |
| DK2968218T3 (da) | Kombination til behandling af parkinsons sygdom | |
| DK3962601T3 (da) | 5-HT2A-agonister til anvendelse til behandling af depression | |
| DK3720433T3 (da) | Bis-cholin-tetrathiomolybdat til behandling af wilsons sygdom | |
| DK3710000T3 (da) | Tradipitant til anvendelse til behandling af gastroparese | |
| DK3643321T3 (da) | Plasminogen til anvendelse i behandling af parkinsons og alzheimers sygdom | |
| ZA201906887B (en) | Bruton's tyrosine kinase inhibitors | |
| DK3463351T3 (da) | Behandling til parkinsons sygdom | |
| DK4005570T3 (da) | Pridopidin til anvendelse behandling af retts syndroe | |
| DK4483956T3 (da) | Troriluzol til anvendelse i behandlingen af spinocerebellar ataksi 3 (sca3) | |
| PL3592355T3 (pl) | Kx2-391/kx-01 do zastosowania w leczeniu rogowacenia słonecznego | |
| CY1127309T1 (el) | Ebselen για χρηση στη θεραπεια της νοσου meniep | |
| PL3850113T3 (pl) | Markery przydatne w strategiach wzbogacania przy leczeniu choroby zwyrodnieniowej stawów | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| DK3761982T3 (da) | Anvendelse af nalfurafin til behandling af demyeliniserende sygdomme | |
| DK3413870T3 (da) | Igmesin til anvendelse ved behandlingen af alzheimers sygdom | |
| MA43764A (fr) | Inhibiteur monovalent de l'interaction hutnfr1 |